Medicare Enrolled
Dr. Erik Zeger, MD
Hematology & Oncology · Wynnewood, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Zeger from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Zeger?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Zeger
Dr. Erik Zeger is a hematology & oncology specialist in Wynnewood, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Zeger performed 79,582 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Zeger received a total of $11,361 from 83 pharmaceutical and/or device companies across 540 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Zeger is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 8% volume in PA
$11,361 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗79,582
Medicare services
Top 8% in PA for hematology & oncology
Not available
Unique patients (not deduplicated)
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
47,250 | $1 | $4 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
21,300 | $0 | $36 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,754 | $0 | $1 |
| Injection, leucovorin calcium, per 50 mg | 2,081 | $3 | $27 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,990 | $1 | $122 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
554 | $101 | $224 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
428 | $24 | $152 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
360 | $107 | $686 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
317 | $12 | $105 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
297 | $69 | $148 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
239 | $23 | $156 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
232 | $52 | $334 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
120 | $52 | $304 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
116 | $145 | $301 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
101 | $11 | $93 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
93 | $1 | $7 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
87 | $1 | $9 |
| New patient office visit, complex (60-74 min) | 85 | $180 | $432 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
75 | $17 | $97 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
52 | $146 | $419 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
23 | $2 | $19 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
14 | $42 | $115 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
14 | $66 | $157 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
60.9% high complexity
37.5% medium
1.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,361
Total received (2018-2024)
Avg $1,623/year across 7 years
Top 21% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
83
Companies
540
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,837
2023
$1,909
2022
$1,578
2021
$563
2020
$605
2019
$2,596
2018
$2,274
Payments by company (2024)
Astellas Pharma US Inc
$259
AstraZeneca Pharmaceuticals LP
$160
Janssen Biotech, Inc.
$137
Novartis Pharmaceuticals Corporation
$125
ABBVIE INC.
$120
PFIZER INC.
$95
Genentech USA, Inc.
$84
GlaxoSmithKline, LLC.
$77
Gilead Sciences, Inc.
$59
Daiichi Sankyo Inc.
$51
Novocure Inc.
$41
Acrotech Biopharma Inc.
$40
SOBI, INC
$37
Bayer Healthcare Pharmaceuticals Inc.
$35
Exelixis Inc.
$34
Mirati Therapeutics, Inc.
$32
Boehringer Ingelheim Pharmaceuticals, Inc.
$31
E.R. Squibb & Sons, L.L.C.
$30
BeiGene USA, Inc.
$29
Incyte Corporation
$29
GENZYME CORPORATION
$24
SERVIER PHARMACEUTICALS LLC
$24
Eisai Inc.
$24
Lilly USA, LLC
$23
Blueprint Medicines Corporation
$23
Fennec Pharmaceuticals, Inc.
$23
Takeda Pharmaceuticals U.S.A., Inc.
$23
Alexion Pharmaceuticals, Inc.
$22
Ipsen Biopharmaceuticals, Inc
$22
Kite Pharma, Inc.
$21
ARRAY BIOPHARMA INC
$21
Deciphera Pharmaceuticals Inc.
$20
Merck Sharp & Dohme LLC
$17
Tempus AI, Inc
$16
Secura Bio, Inc.
$15
Coherus Biosciences Inc.
$14
Top 3 companies account for 30.2% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$791
Celgene Corporation
$705
Novartis Pharmaceuticals Corporation
$698
Genentech USA, Inc.
$686
E.R. Squibb & Sons, L.L.C.
$680
Merck Sharp & Dohme Corporation
$621
PFIZER INC.
$611
AstraZeneca Pharmaceuticals LP
$589
Lilly USA, LLC
$508
Incyte Corporation
$357
Janssen Biotech, Inc.
$355
Pharmacyclics LLC, An AbbVie Company
$301
GlaxoSmithKline, LLC.
$287
GENZYME CORPORATION
$240
Amgen Inc.
$176
Seagen Inc.
$163
JAZZ PHARMACEUTICALS INC.
$160
Ipsen Biopharmaceuticals, Inc
$149
Merck Sharp & Dohme LLC
$138
ABBVIE INC.
$134
Exelixis Inc.
$134
Daiichi Sankyo Inc.
$133
Gilead Sciences, Inc.
$132
AXOGEN
$130
Eisai Inc.
$126
Sirtex Medical Inc
$122
Aurobindo Pharma USA, Inc.
$113
Kite Pharma, Inc.
$103
Blueprint Medicines Corporation
$103
Pharmacyclics LLC, an AbbVie Company
$88
TESARO, Inc.
$88
PUMA BIOTECHNOLOGY, INC.
$74
EISAI INC.
$72
SANOFI-AVENTIS U.S. LLC
$70
Dova Pharmaceuticals
$67
Boehringer Ingelheim Pharmaceuticals, Inc.
$66
Takeda Pharmaceuticals U.S.A., Inc.
$62
AMAG Pharmaceuticals, Inc.
$61
Teva Pharmaceuticals USA, Inc.
$57
Seattle Genetics, Inc.
$56
Taiho Oncology, Inc.
$56
MorphoSys, US Inc.
$55
BeiGene USA, Inc.
$50
Stemline Therapeutics Inc.
$48
SERVIER PHARMACEUTICALS LLC
$48
Apellis Pharmaceuticals, Inc.
$45
Foundation Medicine, Inc.
$42
Novocure Inc.
$41
Acrotech Biopharma Inc.
$40
SOBI, INC
$37
ARRAY BIOPHARMA INC
$37
Bayer Healthcare Pharmaceuticals Inc.
$35
Deciphera Pharmaceuticals Inc.
$33
Mirati Therapeutics, Inc.
$32
Alnylam Pharmaceuticals Inc.
$29
TerSera Therapeutics LLC
$28
Heron Therapeutics, Inc.
$27
Octapharma USA, Inc.
$24
Fennec Pharmaceuticals, Inc.
$23
Sumitomo Pharma America, Inc.
$23
Epizyme, Inc.,
$23
Alexion Pharmaceuticals, Inc.
$22
Karyopharm Therapeutics Inc.
$22
Sobi, Inc
$20
Verastem, Inc.
$20
Fresenius Kabi USA, LLC
$20
Myovant Sciences Inc.
$19
MEDIVATION FIELD SOLUTIONS LLC
$19
Janssen Pharmaceuticals, Inc
$19
Rigel Pharmaceuticals, Inc.
$19
Pharmacosmos Therapeutics Inc.
$18
Amneal Pharmaceuticals LLC
$18
Aadi Bioscience, Inc.
$18
Acrotech Biopharma LLC
$18
Tempus AI, Inc
$16
Mylan Institutional Inc.
$16
Secura Bio, Inc.
$15
Coherus Biosciences Inc.
$14
INSYS Therapeutics Inc
$13
Puma Biotechnology, Inc.
$13
AbbVie, Inc.
$13
Bayer HealthCare Pharmaceuticals Inc.
$13
Clovis Oncology, Inc.
$13
Top 3 companies account for 19.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AVASTIN · AYVAKIT · Abraxane · Alecensa · Avastin · AxoGuard Nerve Protector · BELEODAQ · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · CINVANTI · COPIKTRA · CYRAMZA · Cabometyx · Copiktra · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · EVENITY · Empaveli · Enhertu · Erleada · FERAHEME · FOUNDATIONONE · Folotyn · Fulphila · Fyarro · GAVRETO · GILOTRIF · GIVLAARI · HEMADY · Halaven · IBRANCE · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Optune · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Padcev · Pedmark · Polivy · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUTENT · SYNDROS · Somatuline Depot · Stimufend · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VYXEOS · Vanflyta · Vectibix · Venclexta · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XARELTO · XOSPATA · XPOVIO · XTANDI · Xospata · Xtandi · YONDELIS · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
278
County median income
$111,521
Nearest hospital to ZIP centroid (approximate)
MAIN LINE HOSPITAL LANKENAU
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Zeger is a mixed practice specialist, with above-average Medicare volume (top 8% in PA), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Zeger experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Zeger performed 47,250 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Zeger receive payments from pharmaceutical companies?
Yes. Dr. Zeger received a total of $11,361 from 83 companies across 540 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Zeger's costs compare to other hematology & oncology specialists in Wynnewood?
Dr. Zeger's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Zeger) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Wynnewood
Browse hematology & oncology specialists in Wynnewood ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology